featured
Seladelpar Reduces Alkaline Phosphatase Levels in Patients With Primary Biliary Cholangitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
J. Hepatol. 2022 Aug 01;77(2)353-364, CL Bowlus, MR Galambos, RJ Aspinall, GM Hirschfield, DEJ Jones, Y Dörffel, SC Gordon, SA Harrison, AE Kremer, MJ Mayo, PJ Thuluvath, C Levy, MG Swain, GW Neff, DA Sheridan, CM Stanca, CP Berg, A Goel, ML Shiffman, JM Vierling, P Boudes, A Steinberg, YJ Choi, CA McWherterFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.